Login to Your Account

Other News To Note

Thursday, August 30, 2012
• Noven Pharmaceuticals Inc., of Miami, a subsidiary of Hisamitsu Pharmaceutical Co. Inc., said it submitted a new drug application seeking to market low-dose mesylate salt of paroxetine for the treatment of vasomotor symptoms associated with menopause.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription